Kazia Therapeutics (KZIA) Price & Analysis

Compare

318 Followers

KZIA Stock Chart & Stats

$7.74

-$0.01(-0.57%)

At close: Jan 08 4:00 PM EST

$7.74

-$0.01(-0.57%)

Day’s Range― - ―

52-Week Range$2.86 - $30.05

Previous CloseN/A

Volume31.49K

Average Volume (3M)209.48K

Market Cap

$12.80M

Enterprise ValueN/A

Total Cash (Recent Filing)$3.06M

Total Debt (Recent Filing)$140.74K

Price to Earnings (P/E)―

Beta1.12

Next Earnings

Aug 28, 2025

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding1,670,578

10 Day Avg. Volume60,839

30 Day Avg. Volume209,481

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$16.50

Price Target Upside113.18% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessPaxalisib has shown an overall survival benefit in unmethylated glioblastoma patients of approximately 15 months compared to 12 months with standard-of-care.

Financial OutlookAnalyst's 12-month price target for Kazia has increased to $20, reflecting confidence in paxalisib's potential in both triple-negative breast cancer and glioblastoma multiforme.

Regulatory ProgressKazia Therapeutics has requested a Type C meeting with the FDA to discuss potential accelerated approval for paxalisib in treating newly diagnosed unmethylated glioblastoma patients.

Bears Say

Financial PerformanceKazia reported F2H25 results with a net loss of ($10.2M) and ended the period with $4.3M in cash and equivalents.

Regulatory ChallengesPaxalisib did not meet the primary endpoint in its Phase 2 studies, which may be a point of contention with the FDA.

Regulatory UncertaintyThere remains uncertainty on whether the FDA will request a pre-approval pivotal study prior to NDA submission, as the primary endpoint for all patients was not met in the study.

Kazia Therapeutics News

Closing Bell Movers: Plug Power slips after converible notes offering

U.S. equity futures were slightly higher following sharp declines during the session, as investors digest a growing hang-up...

2d ago

CEG

CARV

Kazia reports results from patient with stage IV TNBC treated with pembrolizumab

Kazia Therapeutics (KZIA) announced that a patient with stage IV triple-negative breast cancer, or TNBC, treated under an...

2d ago

KZIA

Kazia Therapeutics to request FDA Type C meeting

Kazia Therapeutics (KZIA) announced its intention to request and hold a follow-up Type C meeting with the U.S....

25d ago

KZIA

Promising Developments in Oncology Drive Buy Rating for Kazia Therapeutics

In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Kazia Therapeutics, with...

2d ago

KZIA

Kazia Therapeutics Faces Nasdaq Delisting Risk After Compliance Deadline

Kazia Therapeutics ( ($KZIA) ) has provided an update. Kazia Therapeutics Limited announced that it received a staff...

2d ago

KZIA

Kazia Therapeutics Delays 20-F Filing

Kazia Therapeutics ( ($KZIA) ) has released a notification of late filing. Kazia Therapeutics Limited has announced a...

20d ago

KZIA

Buy Rating for Kazia Therapeutics Driven by Promising Paxalisib Developments and Regulatory Catalysts

Maxim Group analyst Naz Rahman reiterated a Buy rating on Kazia Therapeutics yesterday and set a price target...

24d ago

KZIA

Buy Rating for Kazia Therapeutics Driven by Strategic Drug Approval and Licensing Initiatives

Kazia Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sean Lee CFA...

24d ago

KZIA

Strategic Advancements and Potential in Oncology: Kazia Therapeutics’ Buy Rating Driven by Novel PD-L1 Degrader and AI-Driven Paxalisib Development

Kazia Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahman from...

1M ago

KZIA

Kazia Therapeutics Partners with QIMR Berghofer for Innovative PD-L1 Degrader Program

Kazia Therapeutics ( ($KZIA) ) has shared an update. On October 7, 2025, Kazia Therapeutics announced an exclusive...

1M ago

KZIA

Kazia Therapeutics signs collaboration and in-licensing agreement for PD-L1

Kazia Therapeutics (KZIA) announced an exclusive collaboration and in-licensing agreement with QIMR Berghofer for a first-in-class PD-L1 degrader...

1M ago

KZIA

Kazia Therapeutics Reports Significant Tumor Reduction in TNBC Patient with Paxalisib

Kazia Therapeutics ( ($KZIA) ) just unveiled an update. On October 2, 2025, Kazia Therapeutics announced an 86%...

2M ago

KZIA

Kazia Therapeutics price target raised to $20 from $15 at Maxim

Maxim raised the firm’s price target on Kazia Therapeutics (KZIA) to $20 from $15 and keeps a Buy...

2M ago

KZIA

Kazia Therapeutics’ paxalisib combination shows tumor reduction

Kazia Therapeutics (KZIA) reported a substantial reduction in tumor burden from a single-patient expanded access case in triple-negative...

2M ago

KZIA

KZIA FAQ

What was Kazia Therapeutics Limited’s price range in the past 12 months?

Kazia Therapeutics Limited lowest stock price was $2.86 and its highest was $30.05 in the past 12 months.

What is Kazia Therapeutics Limited’s market cap?

Kazia Therapeutics Limited’s market cap is $12.80M.

When is Kazia Therapeutics Limited’s upcoming earnings report date?

Kazia Therapeutics Limited’s upcoming earnings report date is Aug 28, 2025 which is 85 days ago.

How were Kazia Therapeutics Limited’s earnings last quarter?

Currently, no data Available

Is Kazia Therapeutics Limited overvalued?

According to Wall Street analysts Kazia Therapeutics Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kazia Therapeutics Limited pay dividends?

Kazia Therapeutics Limited does not currently pay dividends.

What is Kazia Therapeutics Limited’s EPS estimate?

Kazia Therapeutics Limited’s EPS estimate is >-0.01.

How many shares outstanding does Kazia Therapeutics Limited have?

Kazia Therapeutics Limited has 1,670,578 shares outstanding.

What happened to Kazia Therapeutics Limited’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Kazia Therapeutics Limited?

Currently, no hedge funds are holding shares in KZIA

Company Description

Kazia Therapeutics Limited

Kazia Therapeutics Limited (KZIA) is an innovative oncology-focused biotechnology company based in Australia. It is dedicated to the development and commercialization of novel therapeutics for the treatment of cancer. The company's lead program is paxalisib, a brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is currently in clinical trials for glioblastoma, a highly aggressive form of brain cancer. Kazia Therapeutics aims to address unmet medical needs by advancing its drug candidates through rigorous clinical trials and regulatory processes.

Kazia Therapeutics (KZIA) Earnings & Revenues

Historic Earnings Reports

KZIA Stock 12 Month Forecast

Average Price Target

$16.50

▲(113.18% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","289":"$289","73.75":"$73.8","145.5":"$145.5","217.25":"$217.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,73.75,145.5,217.25,289],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.81,8.747692307692308,9.685384615384615,10.623076923076923,11.560769230769232,12.498461538461537,13.436153846153847,14.373846153846156,15.311538461538461,16.24923076923077,17.186923076923076,18.124615384615385,19.062307692307694,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.81,8.478461538461538,9.146923076923077,9.815384615384616,10.483846153846153,11.152307692307692,11.82076923076923,12.489230769230769,13.157692307692308,13.826153846153847,14.494615384615386,15.163076923076924,15.831538461538461,{"y":16.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.81,8.20923076923077,8.608461538461539,9.007692307692308,9.406923076923077,9.806153846153846,10.205384615384615,10.604615384615386,11.003846153846155,11.403076923076924,11.802307692307693,12.201538461538462,12.600769230769231,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":288,"date":1654041600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96,"date":1659312000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.5,"date":1680307200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.84,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.85,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.63,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.79,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.81,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >